Claims for Patent: 11,267,799

Summary for Patent: 11,267,799

Title:	Solid forms of an HIV capsid inhibitor
Abstract:	The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
Inventor(s):	Shi Bing
Assignee:	Gilead Sciences, Inc.
Application Number:	US15998786
Patent Claims:	2. The crystalline form of claim 1 , wherein the crystalline Form I has at least three XRPD peaks claim 1 , in terms of 2-theta±0.2° claim 1 , selected from 5.6° claim 1 , 6.6° claim 1 , 10.9° claim 1 , 13.4° claim 1 , 16.8° claim 1 , 17.1° claim 1 , 21.8° claim 1 , 24.1° claim 1 , and 26.9°.3. The crystalline form of claim 1 , wherein the crystalline Form I is characterized by an XRPD pattern substantially as shown in .4. The crystalline form of claim 1 , wherein the crystalline Form I is characterized by a DSC thermogram having a melting onset of about 218° C.5. The crystalline form of claim 1 , wherein the crystalline Form I is characterized by a DSC thermogram substantially as shown in .7. The crystalline form of claim 6 , wherein the crystalline Form II has at least three XRPD peaks claim 6 , in terms of 2-theta±0.2° claim 6 , selected from 5.4° claim 6 , 7.0° claim 6 , 11.1° claim 6 , 17.7° claim 6 , 19.2° claim 6 , 21.2° claim 6 , 22.6° claim 6 , 24.0° claim 6 , and 27.7°.8. The crystalline form of claim 6 , wherein the crystalline Form II is characterized by an XRPD pattern substantially as shown in .9. The crystalline form of claim 6 , wherein the crystalline Form II is characterized by a DSC thermogram having a melting onset of about 222° C.10. The crystalline form of claim 6 , wherein the crystalline Form II is characterized by a DSC thermogram substantially as shown in .12. The crystalline form of claim 11 , wherein the crystalline Form III has at least three XRPD peaks claim 11 , in terms of 2-theta±0.2° claim 11 , selected from 5.9° claim 11 , 7.1° claim 11 , 11.6° claim 11 , 15.4° claim 11 , 17.2° claim 11 , 18.4° claim 11 , 19.5° claim 11 , 22.2° claim 11 , and 27.2°.13. The crystalline form of claim 11 , wherein the crystalline Form III is characterized by an XRPD pattern substantially as shown in .14. The crystalline form of claim 11 , wherein the crystalline Form III is characterized by a DSC thermogram having a melting onset of about 213° C.15. The crystalline form of claim 11 , wherein the crystalline Form III is characterized by a DSC thermogram substantially as shown in .16. A pharmaceutical composition comprising the crystalline form of claim 1 , and at least one pharmaceutically acceptable excipient.17. A pharmaceutical composition comprising the crystalline form of claim 6 , and at least one pharmaceutically acceptable excipient.18. A pharmaceutical composition comprising the crystalline form of claim 11 , and at least one pharmaceutically acceptable excipient.19. A method of treating or preventing a human immunodeficiency virus (HIV) infection comprising administering a therapeutically effective amount of the crystalline form of to a subject in need thereof.20. The method of claim 19 , wherein the method comprises administering the crystalline form in combination with one claim 19 , two claim 19 , three claim 19 , or four additional therapeutic agents.